In a recent National Library of Medicine study, researchers opined that cannabidiol has potential as a treatment for cognitive decline, plus Alzheimer’s symptoms. CBD for Alzheimer’s may work by changing the brain chemistry.
Interleukin 33 is a brain-based protein linked to an Alzheimer’s biomarker known as beta-amyloid accumulation. The protein TREM-2 is associated with this progressive neurologic disorder, too.
As per the study’s authors, cannabidiol affected those two proteins in a manner that played a part in the communication of cells in the brain tissue.
The study investigated how cannabidiol affects the brain with a mice model, where a mouse with Alzheimer’s disease would pick between the newly introduced items and what it recognized.
The study author, Hesam Khodadadi stated that Alzheimer’s patients tend to have an impeded style of walking or stiffness. While laboratory mice with this disorder run in a continuous tight circle, cannabidiol treatment stopped that behavior, said Khodadadi.
Researchers injected high dosages of cannabidiol into the stomachs of the mice every second day for a couple of weeks. Consequently, they discovered that cannabidiol normalized IL-33’s levels, which defends findings that that protein could regulate the immune reaction according to the environment. That could lessen inflammation and bring back a state of homeostasis, said the study’s corresponding author Babak Baban.
This study also discovered that cannabidiol made TREM-2 more poignant than it is. Its low levels are associated with Alzheimer’s disease, but after cannabidiol treatment, those went up by tenfold, whereas IL-33’s levels increased by sevenfold.
Cannabidiol is legal in many US states and DC, and its part in medicine keeps growing. Presently, it drives a valuable industry, where experts expect it to get bigger by 15% this decade. Research professionals have also explored the pitfalls and advantages of cannabidiol as a treatment option for Alzheimer’s symptoms.
The Germany-based University Medical Center’s scientists have discovered that tetrahydrocannabinol improved the aptitudes of genetically modified mice with Alzheimer’s disease-like symptoms. Those mice got an artificial form of tetrahydrocannabinol for 6 weeks. When researchers tested it on the memory of those mice, they had success as in the case of the rodents with no Alzheimer’s disease. The mice also did not have neuron loss, plus they experienced a 20% reduction in their untypical beta-amyloid plaques.
With more successful research on THC, CBD and Alzheimer’s disease, we might come close to that day where these two substances become federally-approved treatment options for it.